Have a feature idea you'd love to see implemented?
Let us know!
DXCM Dexcom Inc
Price (delayed)
$69.87
Market cap
$28B
P/E Ratio
40.86
Dividend/share
N/A
EPS
$1.71
Enterprise value
$29.6B
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in
Highlights
Dexcom's net income has soared by 87% YoY and by 4.3% from the previous quarter
The EPS has soared by 84% YoY and by 3.6% QoQ
The quick ratio has grown by 11% year-on-year but it has declined by 2.9% since the previous quarter
Key stats
What are the main financial stats of DXCM
Market
Valuations
Earnings
Shares outstanding
400.73M
Market cap
$28B
Enterprise value
$29.6B
Price to earnings (P/E)
40.86
Price to book (P/B)
11.41
Price to sales (P/S)
7.09
EV/EBIT
36.24
EV/EBITDA
28.96
EV/Sales
7.52
Revenue
$3.93B
EBIT
$816.7M
EBITDA
$1.02B
Free cash flow
$665.5M
Per share
Balance sheet
Liquidity
EPS
$1.71
Free cash flow per share
$1.67
Book value per share
$6.12
Revenue per share
$9.86
TBVPS
$16.69
Total assets
$6.8B
Total liabilities
$4.36B
Debt
$2.54B
Equity
$2.43B
Working capital
$3.13B
Debt to equity
1.04
Current ratio
2.82
Quick ratio
2.36
Net debt/EBITDA
1.56
Margins
Efficiency
Dividend
EBITDA margin
26%
Gross margin
62.7%
Net margin
16.9%
Operating margin
17.3%
Return on assets
10.2%
Return on equity
29.6%
Return on invested capital
12.4%
Return on capital employed
16.1%
Return on sales
20.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DXCM stock price
How has the Dexcom stock price performed over time
Intraday
0.45%
1 week
2.58%
1 month
2.04%
1 year
-11.52%
YTD
-43.69%
QTD
4.22%
Financial performance
How have Dexcom's revenue and profit performed over time
Revenue
$3.93B
Gross profit
$2.47B
Operating income
$681.5M
Net income
$666.9M
Gross margin
62.7%
Net margin
16.9%
Dexcom's net income has soared by 87% YoY and by 4.3% from the previous quarter
DXCM's operating income has surged by 52% year-on-year and by 4.6% since the previous quarter
The net margin has soared by 51% YoY
The operating margin has increased by 24% year-on-year
Growth
What is Dexcom's growth rate over time
Valuation
What is Dexcom stock price valuation
P/E
40.86
P/B
11.41
P/S
7.09
EV/EBIT
36.24
EV/EBITDA
28.96
EV/Sales
7.52
The EPS has soared by 84% YoY and by 3.6% QoQ
The stock's price to earnings (P/E) is 68% less than its 5-year quarterly average of 126.9 and 51% less than its last 4 quarters average of 83.6
DXCM's P/B is 47% below its 5-year quarterly average of 21.6 and 44% below its last 4 quarters average of 20.4
The company's equity rose by 16% YoY and by 8% QoQ
The stock's price to sales (P/S) is 56% less than its 5-year quarterly average of 16.2 and 43% less than its last 4 quarters average of 12.4
Dexcom's revenue has increased by 23% YoY and by 3.5% from the previous quarter
Efficiency
How efficient is Dexcom business performance
The ROE has soared by 71% year-on-year
Dexcom's ROA has soared by 62% YoY and by 4.1% from the previous quarter
DXCM's return on invested capital is up by 32% year-on-year and by 4.2% since the previous quarter
The ROS rose by 30% YoY
Dividends
What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DXCM.
Financial health
How did Dexcom financials performed over time
The company's total assets is 56% higher than its total liabilities
Dexcom's current ratio has increased by 17% YoY but it has decreased by 2.8% QoQ
The quick ratio has grown by 11% year-on-year but it has declined by 2.9% since the previous quarter
The debt is 4.2% more than the equity
DXCM's debt to equity is down by 34% YoY and by 8% QoQ
The debt has decreased by 23% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.